Search
Close this search box.

2O22

Arvinas initiates first registrational study with vepdegestrant

2021

Arvinas partners with Pfizer to co-develop and co-commercialize vepdegestrant

2020

Efficacy proof of concept is achieved for bavdegalutamide and vepdegestrant

2O19

Arvinas PROTAC® degraders, bavdegalutamide and vepdegestrant, enter clinical studies

2O18

Arvinas creates the first blood-brain barrier-crossing PROTAC® protein degrader

2016

Arvinas creates the first oral PROTAC® protein degrader

2O13

Arvinas is founded with the goal to turn protein degraders into patient therapies

2OO1

Arvinas’ founder, Craig Crews, publishes the first paper describing heterobifunctional protein degraders

Search
Close this search box.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content